Mendus Q3 2022: DCP-001 clinical development progresses - Redeye

Redeye comments on Mendus’ Q3 2022 report, as the company is approaching a crucial survival readout from its ADVANCE II trial in AML maintenance therapy with DCP-001. We nudge up our valuation on the back of ALISON phase I safety data.

Länk till analysen i sin helhet: https://www.redeye.se/research/862927/mendus-q3-2022-dcp-001-clinical-development-progresses?utm_source=finwire&utm_medium=RSS